Enovis Corp reported a Schedule 13G ownership disclosure by Vanguard Capital Management. Vanguard reports 2,995,321 shares beneficially owned, representing 5.23% of Enovis common stock. The filing shows sole dispositive power over 2,995,321 shares and sole voting power for 442,970 shares. The report is signed by Vanguard's Head of Global Fund Administration.
Enovis Corp reported that Vanguard Portfolio Management beneficially owned 3,906,658 shares of Common Stock, representing 6.82% of the class as of 03/31/2026. The filing states Vanguard has sole dispositive power for 3,906,658 shares and sole voting power for 98,029 shares. The Schedule 13G filing was signed on 04/29/2026.
Enovis CORP executive Laura Lee Singleton, SVP and Chief HR Officer, filed an initial ownership report. She directly holds 15,552 shares of common stock and an employee stock option covering 1,091 underlying shares at an exercise price of $57.62 per share, expiring on February 27, 2030. The filing also notes unvested restricted stock units and that the option grant vested in three equal installments in 2024, 2025 and 2026.
Enovis Corporation is holding a virtual 2026 annual stockholder meeting on May 19, 2026, where investors will vote on electing ten directors, ratifying Ernst & Young as auditor, an advisory say‑on‑pay vote and an amendment to the 2020 Omnibus Incentive Plan.
For 2025, Enovis reports adjusted earnings per share of $2.24 and adjusted EBITDA of $401.8 million. Annual bonuses for named executives were funded at a company performance factor of 92.2% of target, reflecting net sales and adjusted EBITDA outcomes below internal goals. Long‑term incentives are split between time‑based RSUs and PRSUs tied to relative total shareholder return with a three‑year performance period and a cap at target if absolute TSR is negative.
The proxy highlights a largely independent, MedTech‑experienced board, mandatory director retirement at age 75, robust stock ownership guidelines, a clawback policy, and restrictions on hedging and pledging. In the 2025 advisory vote, approximately 98% of votes cast supported executive pay, which the compensation committee viewed as validation of its pay‑for‑performance framework.
Enovis CORP director Christine Ortiz received a stock grant that increased her direct ownership. On March 31, 2026, she was granted 770 shares of Enovis common stock at a stated price of $0.00 per share, reflecting a compensation-related award rather than an open-market purchase.
After this grant, Ortiz directly holds 15,665 shares of Enovis common stock. The filing shows no accompanying sales or derivative exercises, so this transaction represents a small, routine increase in her equity stake through non-derivative stock compensation.
Enovis Corp received an amended Schedule 13G/A from The Vanguard Group reporting 0 shares beneficially owned, representing 0% of Common Stock as stated in the filing. The amendment explains an internal realignment effective January 12, 2026, under which certain Vanguard subsidiaries report holdings separately.
The filing lists the filer address and certifies no sole or shared voting or dispositive power over Enovis shares. The report is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
Enovis Corp’s Chief Administrative Officer, Oliver Engert, made an open-market purchase of company stock. On March 13, 2026, he bought 1,000 shares of Enovis common stock at $23.74 per share. After this transaction, he directly owns 48,640 shares of Enovis common stock.
This was a straightforward open-market buy, increasing his direct equity stake by a relatively small amount compared with his existing holdings.
Enovis CORP Chief Administrative Officer Oliver Engert bought 1,000 shares of common stock in an open-market purchase at a weighted average price of $23.93 per share. This increases his directly owned stake to 47,640 common shares.
The filing notes the purchase was executed through multiple trades within a price range from $23.75 to $24.10 per share. The transaction represents a relatively small addition compared with his total reported holdings, suggesting a routine increase in personal investment exposure to the company.
Enovis Corp’s principal accounting officer John Kleckner received an equity grant of 14,925 shares of common stock on March 9, 2026. The shares were awarded at no cost as restricted stock units that vest in three equal annual installments beginning on the first anniversary of the grant date.
On March 7, 2026, 586 shares were withheld at $24.51 per share to cover tax obligations tied to a restricted stock unit net settlement, which the company notes is not a sale by Kleckner. Following these transactions, he directly holds 25,884 common shares.
Enovis Corp executive Terry D. Ross, Group President, P&R, received a grant of 36,247 shares of common stock in the form of restricted stock units. These RSUs vest in three equal annual installments beginning on the first anniversary of the grant date.
On a related date, 2,376 shares were withheld by the company at $24.5100 per share to cover tax withholding and remittance obligations tied to the net settlement of RSUs; this did not represent an open-market sale. After these transactions, Ross directly holds 68,477 shares of Enovis common stock.